Biotechnology - Neurological, Asia-Pacific

Filter

Current filters:

NeurologicalAsia-Pacific

Popular Filters

UCB and Biogen sign Asian license agreement for MS drugs

UCB and Biogen sign Asian license agreement for MS drugs

30-01-2014

Belgian drugmaker UCB and US biotech firm Biogen Idec have signed exclusive agreements granting UCB the…

AlprolixAsia-PacificBiogen IdecBiotechnologyEloctateLicensingNeurologicalPharmaceuticalTecfideraUCB

Lundbeck and Otsuka partner on Biotie’s nalmefene in Japan

Lundbeck and Otsuka partner on Biotie’s nalmefene in Japan

31-10-2013

Biotie Therapies says that its partner, Lundbeck has expanded its existing alliance with Otsuka Pharmaceutical…

Asia-PacificBiotechnologyBiotie TherapiesLicensingLundbeckMarkets & MarketingnalmefeneNeurologicalSelincro

Canada's Pharmascience sets up JV with Korea Kolmar; buys Rivex

03-01-2013

Privately-held Canadian drugmaker Pharmascience and Korea Kolmar Holdings, based in Seoul, South Korea,…

Asia-PacificBiotechnologyGenericsHelix BioPharmaKorea KolmarMergers & AcquisitionsNeurologicalNorth AmericaPharmaceuticalPharmascienceRivex Pharma

Sanofi MS drug Aubagio gets second approval, in Australia

21-11-2012

Having already gained approval in the largest global pharma market, the USA, French drug major Sanofi's…

Asia-PacificAubagioBiotechnologyGenzymeNeurologicalPharmaceuticalRegulationSanofi

Regulatory briefs: Celgene's pomalidomide; Lundbeck's vortioxetine

21-09-2012

US biotech firm Celgene (Nasdaq: CELG) says that the US Food and Drug Administration's Oncologic Drugs…

Asia-PacificBiotechnologyCelgeneLundbeckNeurologicalNorth AmericaOncologyPharmaceuticalpomalidomideRegulationvortioxetine

Japanese approval for Regnite and Ranmark

18-01-2012

Japanese drug major Astellas Pharma (TYO: 4503) and USA-based XenoPort (Nasdaq: XNPT) revealed yesterday…

AmgenAsia-PacificAstellas PharmaAstraZenecaBiotechnologyDaiichi SankyodenosumabFinancialNeurologicalOncologyPharmaceuticalRanmarkRegniteRegulationXenoPort

Back to top